Clinical trial
A Multi-Center, Phase 3, Double-Blind, Randomized, and Controlled Trial of KD019 vs Erlotinib in Subjects With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Progressed After First- or Second-Line Chemotherapy
NCT01487174 is registered in ClinicalTrials.gov with Kadmon Corporation, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Phase 3, Double-Blind, Randomized, and Controlled Trial of KD019 vs Erlotinib in Subjects With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Progressed After First- or Second-Line Chemotherapy
- Lead sponsor
- Kadmon Corporation, LLC
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- December 14, 2011
- Completion date
- July 25, 2013
- Enrollment
- 8 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.